NCT02567656View on ClinicalTrials.gov

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

December 10, 2018

Conditions
Lymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous
Interventions
DRUG

RP6530

Tablet starting at 200 mg

Trial Locations (8)

30322

Emory University School of Medicine, Atlanta

48201

Karmanos Cancer Institute, Detroit

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado Cancer Center, Aurora

91010

City of Hope, Duarte

92868

Chao Family Comprehensive Cancer Center University of California Irvine, Orange

48109-0944

University of Michigan Comprehensive Cancer Center, Ann Arbor

44106-5028

University Hospitals Cleveland Medical Center, Cleveland

All Listed Sponsors
lead

Rhizen Pharmaceuticals SA

INDUSTRY

NCT02567656 - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma | Biotech Hunter | Biotech Hunter